New Capital Dynamic European Equity Fund USD Ord AccRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | -1.4 | 23.1 | 2.2 | 7.2 | 7.3 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 21/11/2024 | USD 239.13 | |
Day Change | 0.68% | |
Morningstar Category™ | Other Equity | |
ISIN | IE00BG6MV538 | |
Fund Size (Mil) 21/11/2024 | EUR 129.48 | |
Share Class Size (Mil) 21/11/2024 | USD 1.22 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 31/05/2024 | 1.70% |
Investment Objective: New Capital Dynamic European Equity Fund USD Ord Acc |
The investment objective of the Sub-Fund is to outperform the Benchmark over a rolling 3 year time frame. In seeking to achieve the Sub-Fund’s investment objective, the Sub-Fund will primarily invest in equities and equity-related securities (convertible bonds) of companies worldwide (without any particular geographic, sector or capitalisation focus) that are listed or traded on Recognised Markets worldwide. Consequently the Sub-Fund may have an exposure to emerging markets and such exposure may exceed 20% of the Sub-Fund’s net assets. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Sam Glover 01/11/2021 | ||
Inception Date 11/12/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for New Capital Dynamic European Equity Fund USD Ord Acc | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 3.92 |
AstraZeneca PLC | Healthcare | 3.69 |
ASML Holding NV | Technology | 3.62 |
London Stock Exchange Group PLC | Financial Services | 3.62 |
SAP SE | Technology | 3.56 |
Increase Decrease New since last portfolio | ||
New Capital Dynamic European Equity Fund USD Ord Acc |